Complex medicines for correction of urine pH level during urolithiasis metaphylaxis.
Authors:   the department of N. Lopatkin Scientific Research Institute of urology and Interventional Radiology – branch of the National Medical Research Centre of Radiology of Ministry of health of Russian Federation, Prosyannikov M.Yu. ,   Moscow, Russia, Voytko D.A. ,   N. Lopatkin Scientific Research Institute of urology and Interventional Radiology – branch of the National Medical Research Centre of Radiology of Ministry of health of Russian Federation; Moscow, Russia, Anokhin N.V. ,   the Department of urolithiasis of N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology – Branch of the National Medical Research Radiological Centre; Moscow, Russia, Sivkov A.V. ,   N. Lopatkin Scientific Research Institute of Urol- ogy and Interventional Radiology – Branch of the National Medical Research Centre of Radiology of the Ministry of Health of Russian Federation; Moscow, Russia, Apolikhin O.I. ,   N. Lopatkin Scientific Research Institute of urology and Interventional Radiology – branch of the National Medical Research Centre of Radiology of Ministry of health of Russian Federation; Moscow, Russia, Kaprin A.D. ,   the National Medical Research Centre of Radiology of Ministry of health of Russian Federation, director of P.A. Herzen Institution, Head of Department of Oncology and Radiology named after V.P. Kharchenko of RUDN University; Moscow, Russia
Published: August 2024

Introduction. Urolithiasis is a serious medical, social and economic problem. Over the past decades the world has seen a progressive, approximately 3% per year, increase in its incidence. Urolithiasis occupies a leading position in the structure of urological diseases and has a high recurrence rate in the absence of metaphylaxis. In turn, the effectiveness of properly selected anti-relapse therapy has been proven by many studies and is about 50- 80%. The development of “tools” for rational metaphylaxis represents a potential “growth area” for improving the effectiveness of treatment for patients with urolithiasis. One of these tools is the correction of urine pH levels, since its violations are the most common. However, drugs used to correct pH levels have a number of limitations, which greatly complicates their use. One of the possible solutions to these shortcomings may be the creation of combined drugs that can comprehensively influence the factors that provoke the recurrence of stone formation such as the line of Litcontrol® Litura® products from Devicare (Spain). The purpose of this publication is the scientific rationale of the clinical effects of Litura® Up and Litura® Down in the metaphylaxis of urolithiasis. Materials and methods. A literature search and analysis of foreign and domestic literature was carried out from 1990 to 2024 with the selection of relevant publications in the еLibrary, PubMed databases and Google including keywords – the active components of Lit-Control® pH Up – potassium-magnesium citrate, theobromine, zinc, vitamin A, and Lit-Control® pH Down – phytates, L-methionine, zinc, vitamin A. References in included sources were reviewed to identify additional potentially relevant studies. 189 sources were found, based on the relevance of which 60 articles were selected. Results. The use of Litura® Up and Litura® Down has a scientific basis, and the included substances and their combination potentiate the clinical effect in the metaphylaxis of urolithiasis. However, controlled clinical studies are necessary to assess the prospects for using these complex agents. Conclusions. Based on foreign data from experimental and clinical studies, we can conclude that the Lit-Control® Litura® line of products used to correct urine pH levels and inhibit crystallization in various types of stone formation can be considered as a new promising approach to the metaphylaxis of urolithiasis.